鄭志剛旗下C資本領投智能晶片公司壁仞科技B輪融資
內地智能晶片公司壁仞科技日前宣佈完成B輪融資,聯合領投方為碧桂園(02007.HK)旗下碧桂園創投、中國平安(02318.HK),以及新世界(00017.HK)執行副主席兼行政總裁鄭志剛旗下的C資本。
壁仞科技成立至今累計融資金額已超過47億元人民幣,引入啟明創投、源碼資本、國盛集團國改基金、嘉實資本、招商局資本、貝塔斯曼亞洲投資基金、中信証券投資、沂景資本、中俄投資基金、IDG資本等投資者。
鄭志剛表示,新世界集團堅信科技創新是產業進化的動能,長期關注數字化轉型所帶來的協同效應,用底層技術創新促進生態圈的發展,期待壁仞科技所推動的算力革命賦能產業,重塑消費者體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.